Tokio Marine Asset Management Co. Ltd. Has $936,000 Holdings in Agilent Technologies, Inc. (NYSE:A)

Tokio Marine Asset Management Co. Ltd. lowered its stake in Agilent Technologies, Inc. (NYSE:A) by 1.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,735 shares of the medical research company’s stock after selling 127 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Agilent Technologies were worth $936,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in A. DAVENPORT & Co LLC bought a new position in shares of Agilent Technologies in the third quarter worth about $307,000. Advisory Alpha LLC increased its stake in shares of Agilent Technologies by 38.8% in the third quarter. Advisory Alpha LLC now owns 2,670 shares of the medical research company’s stock worth $299,000 after purchasing an additional 747 shares during the period. Oak Thistle LLC bought a new position in shares of Agilent Technologies in the third quarter worth about $426,000. Czech National Bank increased its stake in shares of Agilent Technologies by 47.5% in the third quarter. Czech National Bank now owns 51,626 shares of the medical research company’s stock worth $5,773,000 after purchasing an additional 16,621 shares during the period. Finally, Handelsbanken Fonder AB increased its stake in Agilent Technologies by 0.5% during the third quarter. Handelsbanken Fonder AB now owns 141,790 shares of the medical research company’s stock valued at $15,855,000 after acquiring an additional 687 shares during the period. Institutional investors and hedge funds own 87.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A has been the topic of several research reports. Oppenheimer boosted their price target on Agilent Technologies from $67.00 to $90.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. Stifel Nicolaus upgraded Agilent Technologies from a “hold” rating to a “buy” rating and boosted their price target for the company from $145.00 to $163.00 in a research note on Friday, April 5th. Citigroup boosted their price target on Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, February 28th. Barclays boosted their price target on Agilent Technologies from $125.00 to $135.00 and gave the company an “underweight” rating in a research note on Wednesday, April 10th. Finally, UBS Group boosted their price target on Agilent Technologies from $130.00 to $155.00 and gave the company a “neutral” rating in a research note on Wednesday, February 28th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $141.29.

Agilent Technologies Stock Up 1.0 %

Shares of A opened at $137.69 on Friday. The business’s 50 day simple moving average is $141.59 and its 200-day simple moving average is $130.56. Agilent Technologies, Inc. has a one year low of $96.80 and a one year high of $151.58. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.68 and a quick ratio of 2.04. The company has a market capitalization of $40.35 billion, a P/E ratio of 32.78, a PEG ratio of 4.17 and a beta of 1.11.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.07. The company had revenue of $1.66 billion for the quarter, compared to the consensus estimate of $1.59 billion. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The firm’s quarterly revenue was down 5.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.37 EPS. As a group, sell-side analysts predict that Agilent Technologies, Inc. will post 5.5 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 24th. Investors of record on Tuesday, April 2nd were given a $0.236 dividend. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date was Monday, April 1st. Agilent Technologies’s dividend payout ratio is currently 22.38%.

Insider Activity at Agilent Technologies

In related news, CEO Michael R. Mcmullen sold 52,297 shares of the company’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $150.00, for a total value of $7,844,550.00. Following the completion of the sale, the chief executive officer now owns 253,909 shares in the company, valued at approximately $38,086,350. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, CEO Michael R. Mcmullen sold 52,297 shares of the company’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $150.00, for a total value of $7,844,550.00. Following the completion of the sale, the chief executive officer now owns 253,909 shares in the company, valued at approximately $38,086,350. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Philip Binns sold 2,827 shares of the stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $147.54, for a total value of $417,095.58. Following the transaction, the senior vice president now owns 9,997 shares of the company’s stock, valued at approximately $1,474,957.38. The disclosure for this sale can be found here. Insiders sold a total of 61,610 shares of company stock worth $9,220,333 in the last quarter. Corporate insiders own 0.33% of the company’s stock.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.